The expression of six biomarkers in the four most common ovarian cancers: Correlation with clinicopathological parameters

APMIS

Volumn 117, Issue 3, 2009, Pages 162-175

  Lin, Chih Kung ^a   Chao, Tai Kuang ^a   Yu, Cheng Ping ^a   Yu, Mu Hsien ^a   Jin, Jong Shiaw ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cortactin; EGFR; Fascin 1; Immunostaining score; MMP 2; MMP 9; Survivin

Indexed keywords

CORTACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FASCIN; FASCIN 1; GELATINASE A; GELATINASE B; SURVIVIN; UNCLASSIFIED DRUG;

ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENDOMETROID ADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, ENDOMETRIOID; CARRIER PROTEINS; CORTACTIN; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICROFILAMENT PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 61349160461     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.00003.x     Document Type: Article

References (33)

1. Jeffrey P, Leon O, John B. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005 7 : 591 600.
2. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obst Gynecol 2002 100 : 281 7.
3. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obst Gynecol 2004 191 : 718 32.
4. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003 20 : 161 9.
5. Xie JJ, Xu LY, Zhang HH, Cai WC, Mai RQ. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun 2005 337 : 355 62.
6. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 2005 37 : 1787 804.
7. Luo ML, Shen XM, Zhang Y, Wei F, Xu X, Cai Y, et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 2006 66 : 11690 9.
8. Roma AA, Prayson RA. Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol 2005 9 : 307 11.
9. Daly RJ. Cortactin signaling and dynamic actin networks. Biochem J 2004 382 : 13 25.
10. Van Rossum AG, Moolenaar WH, Schuuring E. Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 2006 312 : 1658 70.
11. Goncharuk VN, Ross JS, Carlson JA. Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol 2002 29 : 430 8.
12. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-binding protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 2000 83 : 870 3.
13. Pelosi G, Pasini F, Fraggetta F, Pastorino U, Iannucci A, Maisonneuve P, et al. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003 42 : 203 13.
14. Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, et al. Independent prognostic value of fascin immunoreactivity in Stage I non-small cell lung cancer. Br J Cancer 2003 88 : 537 47.
15. Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, et al. Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 2003 162 : 69 80.
16. Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis 2000 18 : 83 8.
17. Tong G.X, Yee H, Chiriboga L, Hernandes O, Waisman J. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Human Pathol 2005 36 : 741 6.
18. Tsai WC, Jin JS, Chang WK, Chan DC, Yeh MK, Chao YC, et al. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. Dis Markers 2007 55 : 955 62.
19. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003 78 : 323 35.
20. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene 1995 159 : 83 96.
21. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997 3 (8) : 917 21.
22. Bauknecht T, Janz I, Kohler M, Pfleiderer A. Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors and EGFR-like factors. Med Oncol Tumor Pharmacother 1989 6 : 121 7.
23. Bauknecht T, Birmelin G, Kommoss F. Clinical significance of oncogenes and growth factors in ovarian carcinomas. J Steroid Biochem Mol Biol 1990 37 : 855 62.
24. Berchuck A, Rodriguez GC, Kamek A, Dodge RK, Soper JT, Clarke DL, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Am J Obstet Gynecol 1991 164 : 669 74.
25. Greenlee RT, Hill-Harmom MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001 51 : 15 36.
26. Partin AW, Shoeniger JS, Mohler LL, DS. Coffey Further analysis of cell motility: correlation of motility with metastatic potentials. Proc Natl Acad Sci 1989 86 : 1254 8.
27. Adams JC. Fascin protrusions in cell interactions. Trends Cardiovasc Med 2004 14 : 221 6.
28. van Rossum AG, Gibcus J, van der Wal J, Schuuring E. Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells. Breast Cancer Res 2005 7 : 235 7.
29. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 2001 20 : 6418 34.
30. Van Rossum AG, Moolenaar WH, Schuuring E. Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 2006 312 : 1658 70.
31. Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, et al. Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 2006 66 : 8017 25.
32. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst (Bethesda) 2002 94 : 1134 42.
33. Zhang B, Pan JS, Liu JY, Han SP, Hu G, Wang B. Effects of chemotherapy and/or radiotherapy on survivin expression in ovarian cancer. Meth Find Exp Clin Pharmacol 2006 28 : 619 25.